GlassScriptPhysician profile
Amanda Young
NPI 1982075735
$8,568.42
in general payments reported to CMS, 2019-2025
51 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,302 · 2022: $1,736 · 2023: $2,073 · 2024: $1,989 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,430.28 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,059.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $677.11 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $496.36 | 2021-2025 | |
| Seagen INC. | $479.08 | 2021-2025 | Padcev, Tukysa, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $468.72 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
| Janssen Biotech, INC. | $405.17 | 2021-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $365.16 | 2021-2025 | Opdivo, Opdualag |
| Incyte Corporation | $308.92 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Myriad Genetic Laboratories, INC. | $282.37 | 2021-2023 | Bracanalysis Cdx |
| Lilly USA, LLC | $250.38 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Array Biopharma INC | $237.35 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Astrazeneca Pharmaceuticals LP | $217.70 | 2023-2025 | Imfinzi, Lynparza, Calquence |
| Abbvie INC. | $194.04 | 2021-2025 | |
| Amgen INC. | $179.26 | 2021-2023 | Kyprolis, Blincyto |
| Stemline Therapeutics INC. | $177.16 | 2022-2024 | Orserdu |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.